Targeting ErbB receptors signaling: A pan-ErbB approach to cancer

Molecular Cancer Therapeutics

Volumn 3, Issue 10, 2004, Pages 1335-1342

  Britten, Carolyn D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CP 724714; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; HYDROXYFLUTAMIDE; LAPATINIB; LETROZOLE; MONOCLONAL ANTIBODY; NAVELBINE; PANITUMUMAB; PELITINIB; PERTUZUMAB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN DERIVATIVE; TAK 165; TRASTUZUMAB; UNCLASSIFIED DRUG; ENZYME INHIBITOR; LIGAND; PROTEIN TYROSINE KINASE;

ANOREXIA; CANCER CELL; CARDIOTOXICITY; CELL MEMBRANE; CELL TRANSFORMATION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TARGETING; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NAUSEA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SHORT SURVEY; SIGNAL TRANSDUCTION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VALIDATION PROCESS; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; METABOLISM; NEOPLASM; PROTEIN BINDING; PROTEIN MOTIF; REVIEW;

AMINO ACID MOTIFS; ANIMALS; ENZYME INHIBITORS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 7444239715     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (74)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-37.
2. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-99.
3. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
4. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 19961- 16:5276-87.
5. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
7. Paez JG, Jenne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-500.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
9. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244: 707-12.
10. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992;10:1044-8.
11. Kokai Y, Myers JN, Wade T, et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 1989;58:287-92.
12. Alimandi M, Romano A, Curia MC, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995;10:1813-21.
13. Tateishi M, Ishida T, Kohdono S, Hamatake M, Fukuyama Y, Sugimachi K. Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 1994;3:109-13.
14. Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/ neu and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999;5: 4164-74.
15. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-5.
16. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54.
17. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48.
18. Barbacci EG, Pustilnik LR, Rossi AMK, et al. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer Res 2003;63:4450-9.
19. Wissner A, Brawner Floyd MB, Rabindran SR, et al. Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolies currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorg Med Chem Lett 2002;12:2893-7.
20. Jani JP, Barbacci G, Bhattacharya S, et al. CP-724714, a novel erbB2 receptor tyrosine kinase inhibitor for cancer therapy [abstract]. Proc AACR 2004;45:4637.
21. Naito K, Matsutani E, Tamura T, et al. TAK-165, a selective inhibitor of HER2 tyrosine kinase. I. Nature of tyrosine kinase inhibition and selective antitumor activity in vivo and in vitro [abstract]. Proc AACR 2002;43:3897.
22. Allen LF, Eiseman IA, Fry DW, Lenehan PF. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol 2003;30:65-78.
23. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
24. Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499-512.
25. Riese DJ, Stern DF. Specificity within the EGFR family/ErbB receptor family signaling network. BioEssays 1998;20:41-8.
26. Samanta A, LeVea CM, Dougall WC, Quian X, Greene MI. Ligand and p185c-neu density govern receptor interactions and activation. Proc Natl Acad Sci U S A 1994;91:1711-5.
27. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65.
28. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12:541-52.
29. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003;11:507-17.
30. Cho HS, Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002;297:1330-3.
31. Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002;110:775-87.
32. Garrett TP, McKern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell 2002;110:763-73.
33. Gullick WJ. A new model for the interaction of EGF-like ligands with their receptors: the new one-two. Eur J Cancer 1994;30A:2186.
34. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60.
35. Garrett TP, McKern NM, Lou M, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003;11:495-505.
36. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 1998;18:5042-51.
37. Lenferink AEG, Pinkas-Kramarski R, van de Poll MLM, et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998;17:3385-97.
38. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002;62:3151-8.
39. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95.
40. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61: 7184-8.
41. Normanno N, Campiglio M, De Luca A, et al. Cooperative inhibitor effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13:65-72.
42. Finn RS, Wilson CA, Chen J, et al. Biologic effects of CP-724,714, a selective HER-2/neu kinase inhibitor, on human breast cancer cells with variable expression of EGFR and HER-2 [abstract]. Proc AACR 2004; 45:4556.
43. Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res 1999;5:2171-7.
44. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999;18:731-8.
45. Ritter CA, Bianco R, Dugger T, et al. HER2-overexpressing human breast cancer cells selected for Herceptin (trastuzumab) resistance in vivo retain HER2 gene amplification and overexpress HER1/EGF receptor ligands [abstract]. Proc AACR 2003;44:R4869.
46. Konecny G, Finn R, Venkatesan N, et al. The novel dual kinase inhibitor GW572016 is particularly active in HER2-positive and trastuzumab-conditioned breast cancer cells [abstract]. Breast Cancer Res Treat 2003;82:S171.
47. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
48. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-51.
49. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-95.
50. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004;96:759-69.
51. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
52. Britten CD, Pegram M, Rosen P, et al. Targeting ErbB receptor interactions: a phase I trial of trastuzumab and erlotinib in metastatic HER2+ breast cancer [abstract]. Proc Am Soc Clin Oncol 2004;23: 3045.
53. Moulder SL, Arteaga CL. A phase I/II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpresses HER2/neu (ErbB-2). Clin Breast Cancer 2003;4:142-5.
54. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70.
55. Citri A, Alroy I, Lavi S, et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J 2002;21:2407-17.
56. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18: 2349-51.
57. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;28:126-42.
58. Rowinsky EK, Garrison M, Lorusso P, et al. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor is feasible on a 7-day-on/7-day-off schedule: a phase I, pharmacokinetic, and food effect study [abstract]. Proc Am Soc Clin Oncol 2003;22:807.
59. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFr/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-63.
60. ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23:646-53.
61. Burris HA, Taylor C, Jones S, et al. A phase I study of GW572016 in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol 2003;22:994.
62. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 2004;23: 3006.
63. Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002;8:3496-502.
64. Culy CR, Faulds D. Gefitinib. Drugs 2002;62:2237-48.
65. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50:1550-8.
66. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update of trastuzumab and 2C4. Adv Exp Med Biol 2003;532:253-68.
67. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2: 127-37.
68. Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 2002;62:5485-8.
69. Jackson JG, St. Clair P, Sliwkowski MX, Brattain MG. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-erbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004;64:2601-9.
70. Agus DB, Gordon M, Taylor C, et al. Clinical activity in a phase I trial of HER-2-targeted rhuMab 2C4 (pertuzumab) in patients with advanced solid malignancies [abstract]. Proc Am Soc Clin Oncol 2003;22:771.
71. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6.
72. Johnson BE, Lucca J, Rubin MS, et al. Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma [abstract]. Proc Am Soc Clin Oncol 2004;23:7080.
73. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer following failure of 1st or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group trial. Proc Am Soc Clin Oncol 2004;23:7022.
74. Arteaga CL. Selecting the right patient for tumor therapy. Nat Med 2004;10:577-8.